October 21, 2024
Current Four-generation ADCs and Next-generation ADCs
Since the first ADC drug Mylotarg (gemtuzumab ozogamicin) was approved by the FDA in 2000, a total of 15 ADC drugs have been approved for marketing worldwide to treat hematological malignancies and solid tumors. In addition, more than 400 ADC drugs are in different stages of development. Of the 15 approved ADC drugs, 13 are […]
Read More >
